Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study

Horizon Therapeutics announced positive top-line results from its phase IV study of Tepezza for the treatment of Thyroid Eye Disease (TED) in adult patients with chronic/low clinical activity scores (CAS). Notably, CAS is a measure of disease activity. The phase IV study is being conducted to better inform physicians and payers on the safety and efficacy of TEPEZZA in TED patients with a low CAS.